Trial Profile

The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Zanubrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Doxorubicin liposomal; Epirubicin; Orelabrutinib; Prednisone; Vincristine
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use

Most Recent Events

13 Dec 2022 Results(n=38) assessing efficacy of BTK Inhibitors in Combination with Rituximab and Lenalidomide (BTKiR2) for Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition
28 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com